Jamal Misleh is an Oncology physician affiliated with Medical Oncology Hematology Consultants. OpenAlex indexes 163 publications with 711 citations (h-index 11).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4701 Ogletown Stanton Rd
Suite 3400
Newark, DE 197132055
Telephone
302-366-1200Registry record last updated 15 Jun 2009.
Industry payments
27 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year20254 payments
- Regeneron Healthcare Solutions, Inc.Program year20251 payment
- Ipsen Biopharmaceuticals, IncProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
54.2%PD-1 inhibitor17.5%Pembrolizumab100%Part B, office-administered≥37 patientsCD38-directed Cytolytic Antibody15%Daratumumab100%Part B, office-administered≥32 patients+ 15 more classes in this area
Blood & clotting
27.4%Erythroid Maturation Agent15%Luspatercept-aamt100%Part B, office-administered≥12 patientsErythropoiesis-stimulating Agent8.3%Darbepoetin alfa100%Part B, office-administered≥24 patients+ 2 more classes in this area
Anti-infectives
6.8%Human Immunoglobulin G6.8%Immune globulin100%Part B, office-administered≥30 patientsShort-acting sulfonamides0%Sulfamethoxazole-Trimethoprim100%Part D≥25 patients+ 5 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”